Palvella Therapeutics' (PVLA) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• Palvella Therapeutics' stock is reaffirmed with a "sell (d-)" rating by Weiss Ratings, while other firms like Cantor Fitzgerald and Lifesci Capital offer more optimistic ratings.
• The company reported a quarterly loss of ($0.86) EPS, missing estimates, and is predicted to post a loss of ($3.69 EPS for the current year.
• Palvella has seen varied institutional investment activity, with hedges increasing their stakes and owning 40.11% of the company's stock.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report)'s stock had its "sell (d-)" rating restated by analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

PVLA has been the subject of a number of other reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $120.00 price target on shares of Palvella Therapeutics in a research note on Tuesday. Lifesci Capital started coverage on Palvella Therapeutics in a report on Monday, August 4th. They set an "outperform" rating and a $90.00 price target on the stock. Canaccord Genuity Group lifted their price target on Palvella Therapeutics from $52.00 to $66.00 and gave the company a "buy" rating in a report on Tuesday, August 19th. Raymond James Financial set a $54.00 target price on Palvella Therapeutics and gave the stock an "outperform" rating in a report on Tuesday, August 5th. Finally, Oppenheimer initiated coverage on Palvella Therapeutics in a report on Tuesday, September 9th. They set an "outperform" rating and a $85.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Palvella Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $73.50.

Palvella Therapeutics Trading Up 5.8%

Shares of PVLA opened at $74.85 on Wednesday. The firm has a market capitalization of $827.84 million, a P/E ratio of -6.19 and a beta of -0.13. The stock's fifty day simple moving average is $53.41 and its 200 day simple moving average is $34.97. Palvella Therapeutics has a twelve month low of $11.17 and a twelve month high of $76.22.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.08). Sell-side analysts predict that Palvella Therapeutics will post -3.69 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Palvella Therapeutics during the second quarter worth approximately $37,000. Spire Wealth Management bought a new position in Palvella Therapeutics in the first quarter valued at approximately $70,000. JPMorgan Chase & Co. boosted its stake in Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company's stock valued at $73,000 after acquiring an additional 3,242 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Palvella Therapeutics during the second quarter worth $85,000. Finally, BNP Paribas Financial Markets bought a new position in shares of Palvella Therapeutics during the second quarter worth $104,000. Institutional investors and hedge funds own 40.11% of the company's stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.